Nile Therapeutics, Inc. Share Price Other OTC
Equities
US6541451018
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 22.24M 1.75B | Sales 2025 * | 48.5M 3.81B | Capitalization | 167M 13.1B |
---|---|---|---|---|---|
Net income 2024 * | -38M -2.99B | Net income 2025 * | -29M -2.28B | EV / Sales 2024 * | 7.49 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.44 x |
P/E ratio 2024 * |
-4.45
x | P/E ratio 2025 * |
-5.95
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.74% |
Latest transcript on Nile Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 19/11/13 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 19/11/13 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 20/07/23 |
Earl Collier
BRD | Director/Board Member | 76 | 19/11/13 |
George Dunbar
BRD | Director/Board Member | 77 | 19/11/13 |
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.31% | 22.78B | |
-10.63% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |